FR2773324A1 - Composition for filling in wrinkles by injection - Google Patents

Composition for filling in wrinkles by injection Download PDF

Info

Publication number
FR2773324A1
FR2773324A1 FR9800003A FR9800003A FR2773324A1 FR 2773324 A1 FR2773324 A1 FR 2773324A1 FR 9800003 A FR9800003 A FR 9800003A FR 9800003 A FR9800003 A FR 9800003A FR 2773324 A1 FR2773324 A1 FR 2773324A1
Authority
FR
France
Prior art keywords
pharmaceutical composition
glucomannan
composition according
wrinkles
filling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR9800003A
Other languages
French (fr)
Other versions
FR2773324B1 (en
Inventor
Gerard Amsellem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to FR9800003A priority Critical patent/FR2773324B1/en
Publication of FR2773324A1 publication Critical patent/FR2773324A1/en
Application granted granted Critical
Publication of FR2773324B1 publication Critical patent/FR2773324B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition for filling in wrinkles by injection comprises glucomannan (30-99) and excipients or carriers (1-70 %).- ACTIVITY - None given.- MECHANISM OF ACTION - None given

Description

Nouvelles préparations à base de olucomannane
et leur utilisation dans le domaine de la médecine
esthétique et réparatrice
La présente invention se rapporte au domaine de la dermatologie et plus particulièrement à celui de la médecine esthétique.New preparations based on olucomannan
and their use in medicine
aesthetic and restorative
The present invention relates to the field of dermatology and more particularly to that of aesthetic medicine.

L'invention a plus précisément pour objet de nouvelles compositions injectables destinées à combler les dépressions de l'épiderme dues principalement aux rides et aux cicatrices. The invention more specifically relates to new injectable compositions intended to fill depressions in the epidermis due mainly to wrinkles and scars.

L'invention concerne spécifiquement de nouvelles compositions à base de
Glucomannane et caractérisées en ce qu'elles contiennent principalement des fibres d'origine végétale hydrosolubles gélifiantes et douées d'une très grande viscosité.The invention relates specifically to new compositions based on
Glucomannan and characterized in that they mainly contain fibers of water-soluble gelling vegetable origin and endowed with a very high viscosity.

Le comblement des rides et cicatrices s'effectue classiquement par l'injection sous cutanée de matériaux de comblement. The filling of wrinkles and scars is conventionally carried out by subcutaneous injection of filling materials.

Les matériaux utilisés sont la plupart du temps des gels d'origine animale bovine comme les collagènes ou aviaires comme l'acide hyaluronique.The materials used are mostly gels of bovine animal origin such as collagens or avians such as hyaluronic acid.

L'utilisation de ces gels n'est pas sans poser de problèmes notamment par le risque de transmission virale et, ou de réactions antigéniques.The use of these gels is not without problems, in particular by the risk of viral transmission and, or of antigenic reactions.

D'autre part les collagènes sont biodégradables et leur efficacité s'amenuise avec le temps ce qui nécessite des interventions successives pour maintenir les résultats souhaités.On the other hand, collagens are biodegradable and their effectiveness decreases over time, which requires successive interventions to maintain the desired results.

Il s'est avéré intéressant de mettre au point de nouvelles substances gélifiantes d'origine végétale et destinées à etre utilisées en médecine esthétique et réparatrice.It has proven to be interesting to develop new gelling substances of plant origin and intended for use in aesthetic and restorative medicine.

Cet objectif est réalisé avec les compositions selon l'invention qui associent une ou plusieurs fibres d'origine végétale ou synthétique seules ou en mélanges.This objective is achieved with the compositions according to the invention which combine one or more fibers of plant or synthetic origin alone or in mixtures.

Le glucomannane, principal constituant du Konjac appelé aussi Konyaku répond parfaitement à ces critères de choix.Glucomannan, the main constituent of Konjac, also called Konyaku, perfectly meets these selection criteria.

Le glucomannane est extrait d'un bulbe végétal l'Amorphophallus Rivieri variété
Konjac dénommé Konjac ou Konyaku cultivé traditionnellement en Asie. Glucomannan is extracted from a plant bulb, the Amorphophallus Rivieri variety
Konjac called Konjac or Konyaku traditionally cultivated in Asia.

Arrivé à maturité le bulbe est recueilli puis séché , broyé et purifié selon des méthodes traditionnelles.When mature, the bulb is collected and then dried, crushed and purified according to traditional methods.

Le glucomannanejprincipal constituant du bulbe est un polysaccharide qui forme un gel en présence d'eau à la température ambiante.The main constituent of the bulb glucomannan is a polysaccharide which forms a gel in the presence of water at room temperature.

L'hydrolyse acide compléte ainsi que la chromatographie en phase gazeuse ont permis de déterminer comme seuls constituants de ce polysaccharide le D glucose et le D mannose.The complete acid hydrolysis as well as the gas chromatography made it possible to determine as the only constituents of this polysaccharide D glucose and D mannose.

L'évaluation quantitative du D mannose et du D glucose contenu dans l'hydrolysat indique un rapport moléculaire D mannose / D glucose de 1,6 .The quantitative evaluation of D mannose and D glucose contained in the hydrolyzate indicates a molecular ratio D mannose / D glucose of 1.6.

IL a d'autre part été démontré que le glucomannane était constitué d'une chaîne principale formée uniquement d'une liaison 14 des deux sucres simples selon la séquence présentée sur la formule (I).It has also been demonstrated that glucomannan consists of a main chain formed only of a bond 14 of the two simple sugars according to the sequence presented in formula (I).

Généralement la chaîne est constituée par la succession linéaire de 13 hexoses.

Figure img00020001
Generally the chain is constituted by the linear succession of 13 hexoses.
Figure img00020001

Formule linéaire du Glucomannane de Koniac (I)
G= Glucose
M= Mannose
L'extraction du glucomannane s'effectue à partir de la poudre totale du tubercule.Koniac Glucomannan linear formula (I)
G = Glucose
M = Mannose
The glucomannan is extracted from the total powder of the tuber.

Après traitement et broyage on obtient une poudre granuleuse contenant au moins 75 % de Glucomannane.After treatment and grinding, a granular powder is obtained containing at least 75% of Glucomannan.

Le Glucomannane est alors concentré et purifié pour atteindre une pureté d'environ 90% selon diverses méthodes dont la plus fiable est celle de Sugiyama.The Glucomannan is then concentrated and purified to reach a purity of around 90% according to various methods, the most reliable of which is that of Sugiyama.

Les essais ont montré que la poudre de Konjac ne présentait aucune toxicité par voie orale de même que les produits de son hydrolyse c'est à dire le glucose et le mannose, deux sucres bien connus.Tests have shown that Konjac powder had no oral toxicity, as did the products of its hydrolysis, namely glucose and mannose, two well-known sugars.

D'un point de vue physique, le glucomannane en présence d'eau se transforme en gel dont la viscosité peut aller de 10.000 cps à 120.000 cps selon la qualité et la pureté de la matière première.From a physical point of view, glucomannan in the presence of water turns into a gel whose viscosity can range from 10,000 cps to 120,000 cps depending on the quality and purity of the raw material.

Le glucomannane n'est pas dégradé par les enzymes de l'organisme.Glucomannan is not broken down by the body's enzymes.

Les préparations selon l'invention se caractérisent par le fait que les fibres utilisées sont d'origine végétale, dépourvues de toxicité, extrêmement hygroscopique, gélifiantes et non dégradés par l'organisme, caractérisées en ce quelles comprennent de 30 à 99% de Glucomannane à titre de principe actif et de 1% à 70% d'excipients ou de véhicules pharmaceutiques acceptables. The preparations according to the invention are characterized in that the fibers used are of plant origin, devoid of toxicity, extremely hygroscopic, gelling agents and not degraded by the organism, characterized in that they comprise from 30 to 99% of Glucomannan to as active ingredient and from 1% to 70% of acceptable excipients or pharmaceutical vehicles.

Le Glucomannane sera utilisé seul ou associé à des extraits d'algues ou à d'autres fibres végétales comme l'agar agar, la gomme Xanthane, la gomme de sterculia, les extraits de cellulose.Glucomannan will be used alone or combined with seaweed extracts or other plant fibers such as agar agar, Xanthan gum, sterculia gum, cellulose extracts.

Le gel, une fois réalisé après incorporation de la quantité d'eau nécessaire à l'obtention de la viscosité voulue fera l'objet d'une décontamination soit mécanique, soit par rayonnement stérilisant, soit par les deux méthodes.The gel, once produced after incorporating the amount of water necessary to obtain the desired viscosity, will be subject to decontamination either mechanically, or by sterilizing radiation, or by both methods.

La préparation pharmaceutique ainsi obtenue sera alors conditionnée en seringues stériles pré remplies et prêtes à l'emploi. The pharmaceutical preparation thus obtained will then be packaged in sterile syringes pre-filled and ready for use.

Claims (6)

REVENDICATIONS 1. composition pharmaceutique destinée au comblement des rides par injection et caractérisée en ce qu'elle comprend de 30 à 99% de Glucomanane à titre de principe actif et de 1 à 70 % d'autres excipients, supports ou véhicules pharmaceutiques acceptables. 1. pharmaceutical composition intended for filling wrinkles by injection and characterized in that it comprises from 30 to 99% of Glucomanane as active ingredient and from 1 to 70% of other acceptable pharmaceutical excipients, carriers or vehicles. 2. composition pharmaceutique selon la revendication 1 caractérisée en ce qu'elle est constituée d'un mélange de fibres végétales et d'eau. 2. pharmaceutical composition according to claim 1 characterized in that it consists of a mixture of plant fibers and water. 3. composition pharmaceutique selon les revendications précédentes caractérisée en ce que le glucomannane provient de la poudre de l'Amorphophallus Konjac. 3. Pharmaceutical composition according to the preceding claims, characterized in that the glucomannan comes from the powder of Amorphophallus Konjac. 4. composition pharmaceutique selon les revendications 1 et 2 caractérisée en ce qu'elle est décontaminée et stérilisée. 4. pharmaceutical composition according to claims 1 and 2 characterized in that it is decontaminated and sterilized. 5.composition pharmaceutique selon une des revendications 1 à 4 caractérisée en ce qu'elle est présentée sous forme de seringue pré remplie. 5. Pharmaceutical composition according to one of claims 1 to 4 characterized in that it is presented in the form of a pre-filled syringe. 6. composition pharmaceutique selon les revendications 1 et 2 caractérisée en ce qu'elle est présentée sous forme de gel.  6. pharmaceutical composition according to claims 1 and 2 characterized in that it is presented in the form of a gel.
FR9800003A 1998-01-02 1998-01-02 NOVEL GLUCOMANNAN PREPARATIONS AND THEIR USE IN THE FIELD OF AESTHETIC AND REPAIRING MEDICINE Expired - Fee Related FR2773324B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR9800003A FR2773324B1 (en) 1998-01-02 1998-01-02 NOVEL GLUCOMANNAN PREPARATIONS AND THEIR USE IN THE FIELD OF AESTHETIC AND REPAIRING MEDICINE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9800003A FR2773324B1 (en) 1998-01-02 1998-01-02 NOVEL GLUCOMANNAN PREPARATIONS AND THEIR USE IN THE FIELD OF AESTHETIC AND REPAIRING MEDICINE

Publications (2)

Publication Number Publication Date
FR2773324A1 true FR2773324A1 (en) 1999-07-09
FR2773324B1 FR2773324B1 (en) 2000-06-16

Family

ID=9521506

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9800003A Expired - Fee Related FR2773324B1 (en) 1998-01-02 1998-01-02 NOVEL GLUCOMANNAN PREPARATIONS AND THEIR USE IN THE FIELD OF AESTHETIC AND REPAIRING MEDICINE

Country Status (1)

Country Link
FR (1) FR2773324B1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480654A1 (en) * 2002-02-15 2004-12-01 Ultraceuticals R&D Pty Limited Carbohydrate-based anti-wrinkle and tissue remodelling compounds
FR2940608A1 (en) * 2008-12-30 2010-07-02 Oreal USE OF MONOSACCHARIDES AND COMPOSITION
FR2940610A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH C-GLYCOSIDE DERIVATIVES AND ITS USE IN COSMETICS
US20100255076A1 (en) * 2007-10-04 2010-10-07 Ultraceuticals R & D Pty Ltd Composition and method for dermal regeneration
EP3040104A1 (en) * 2014-12-29 2016-07-06 Shyam Prasad Kodimule Compositions of amorphophallus konjac extract and methods for their use in skin care
US9421157B2 (en) 2006-07-03 2016-08-23 L'oreal Use of C-glycoside derivatives as pro-desquamating active agents
FR3098719A1 (en) * 2019-07-19 2021-01-22 Laboratoire Promicea New makeup and / or lip care composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2120009A1 (en) * 1970-12-30 1972-08-11 Shimizu Manzo Shoten Kk
JPS5795905A (en) * 1980-12-05 1982-06-15 Kyoei Kagaku Kogyo Kk Cosmetic
JPH0761938A (en) * 1993-08-25 1995-03-07 Shimizu Kagaku Kk Medicinal composition for external use consists of hydrophilic polysaccharides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2120009A1 (en) * 1970-12-30 1972-08-11 Shimizu Manzo Shoten Kk
JPS5795905A (en) * 1980-12-05 1982-06-15 Kyoei Kagaku Kogyo Kk Cosmetic
JPH0761938A (en) * 1993-08-25 1995-03-07 Shimizu Kagaku Kk Medicinal composition for external use consists of hydrophilic polysaccharides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9518, Derwent World Patents Index; Class B04, AN 95-136799, XP002079724 *
PATENT ABSTRACTS OF JAPAN vol. 006, no. 180 (C - 125) 14 September 1982 (1982-09-14) *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480654A1 (en) * 2002-02-15 2004-12-01 Ultraceuticals R&D Pty Limited Carbohydrate-based anti-wrinkle and tissue remodelling compounds
EP1480654A4 (en) * 2002-02-15 2007-11-14 Ultraceuticals R & D Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US9421157B2 (en) 2006-07-03 2016-08-23 L'oreal Use of C-glycoside derivatives as pro-desquamating active agents
EP2229175A4 (en) * 2007-10-04 2015-06-17 Ultraceuticals R & D Pty Ltd Composition and method for dermal regeneration
US20100255076A1 (en) * 2007-10-04 2010-10-07 Ultraceuticals R & D Pty Ltd Composition and method for dermal regeneration
AU2008307152B2 (en) * 2007-10-04 2013-10-10 Ultraceuticals R & D Pty Ltd Composition and method for dermal regeneration
US9433805B2 (en) * 2007-10-04 2016-09-06 Ultraceuticals R&D Pty Ltd. Method for dermal regeneration by administering an ether cross-linked glucomannan/hyaluronic acid composition
EP2204162A1 (en) * 2008-12-30 2010-07-07 L'oreal Use of monosaccharides and composition
EP2206491A1 (en) * 2008-12-30 2010-07-14 L'oreal Association of monosaccharides and C-glycoside derivatives and its use in cosmetics
US8445459B2 (en) 2008-12-30 2013-05-21 L'oreal Combination of monosaccharide with C-glycoside derivative and use thereof
FR2940610A1 (en) * 2008-12-30 2010-07-02 Oreal ASSOCIATION OF MONOSACCHARIDES WITH C-GLYCOSIDE DERIVATIVES AND ITS USE IN COSMETICS
US9364411B2 (en) 2008-12-30 2016-06-14 L'oreal Use of monosaccharides and composition therefor
FR2940608A1 (en) * 2008-12-30 2010-07-02 Oreal USE OF MONOSACCHARIDES AND COMPOSITION
EP3040104A1 (en) * 2014-12-29 2016-07-06 Shyam Prasad Kodimule Compositions of amorphophallus konjac extract and methods for their use in skin care
FR3098719A1 (en) * 2019-07-19 2021-01-22 Laboratoire Promicea New makeup and / or lip care composition

Also Published As

Publication number Publication date
FR2773324B1 (en) 2000-06-16

Similar Documents

Publication Publication Date Title
EP1968711B1 (en) Dermatological viscoelastic gel
CA1052307A (en) Method for the extraction and processing of glycoproteins, mucopolysaccharides and accompanying substances
US7135164B2 (en) Andrographis paniculata gel as an adjunct in the treatment of periodontitis
US6803454B2 (en) Method for extraction and purification of cartilage type proteoglycan
CN106794210A (en) Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition
CN109528583A (en) A kind of antibacterial anti-inflammatory analgesic mouthwash and preparation method thereof
JPH05503522A (en) Novel cosmetic product containing extract of lipid-free seeds of sunflower (Helianthus annuus)
FR2773324A1 (en) Composition for filling in wrinkles by injection
Abedi et al. Antioxidant materials in oral and maxillofacial tissue regeneration: a narrative review of the literature
RU2450816C2 (en) Compositions of hyaluronic acid salt for epithelial damages
JP5294536B2 (en) Gingival epithelial cell spreading inhibitor
KR101599907B1 (en) Antioxidant Comprising Extracts of Natural Materials and Uses Thereof
JP6821210B1 (en) Throat spray
CN101365464A (en) Use of epoxidised compounds
Kishore et al. Coconut Palm (Cocos nucifera L.) A Natural Gift to Humans for Dental Ministration
KR970069019A (en) Method of manufacturing powdered toothpaste for prevention and treatment of taste, tooth decay, tooth decay
EP1415646B1 (en) Gel comprising antimicrobial extract as an adjunct in the treatment of periodontitis
KR102588162B1 (en) Oral preparations containing water-soluble chitosan and manufacturing method thereof
DE60023585T2 (en) Preparation of a medicament containing catechol- or flavonylic-like polyphenol compounds from plants, in particular for the treatment of gingivitis
DeShmukh et al. Smear Layer Removal Efficacy of Natural Root Canal Irrigants-A Literature Review.
Hosseini et al. A novel binary chlorhexidine-chitosan irrigant with high permeability, and long lasting synergic antibacterial effect.
KR20190096088A (en) Production method for natural toothpaste using lettuce
CN1859852A (en) Morinda citrifolia-based oral care compositions and methods
SU942756A1 (en) Dental paste
CN106492152A (en) A kind of skin surface disinfecting anti inflammatory agent and preparation method thereof

Legal Events

Date Code Title Description
ST Notification of lapse